A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
NCT02185040
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
Systemic Lupus Erythematosus
Interventions
DRUG:
CC-220
DRUG:
CC-220
DRUG:
CC-220
DRUG:
CC-220
DRUG:
Placebo
Sponsor
Celgene